… announced that the FDA has accepted its new drug application (NDA … 05 as a potential remedy for treatment-resistant depression (“TRD”), … clinical data on reboxetine, the active pharmaceutical ingredient in AXS … ranked company from the biotech sector, sporting a …

… showed two classes of medication, reboxetine and butylbromide, were able … ; airways, with the drugs reducing the severity of … thrilled because the current treatment options for people … placebo-controlled, randomised crossover trial. Journal of Physiology. doi …

… limited treatment options. Results from two placebo-controlled trials demonstrate … In the phase 3 trial, 1,122 patients with … In the phase 2 trial, 267 patients with fibromyalgia … reboxetine. AXS-14 is an investigational drug product not approved by the FDA …

… in the treatment of narcolepsy; trial initiation … clinical trials of patients treated with reboxetine, and … potentially life-changing medicines for the … Drug Administration (FDA) Breakthrough Therapy designation and Orphan Drug Designation for the treatment …

… for AXS-12 for the treatment of narcolepsy, has been … Therapy meeting with the FDA. Narcolepsy is a neurological … includes one Phase 3 efficacy trial, which, along with the … completed clinical pharmacology studies of reboxetine, previously obtained through an …

… American Academy of Sleep Medicine (AASM) and … -12 AXS-12 (reboxetine) is a highly selective … Drug Administration (FDA) Breakthrough Therapy designation and Orphan Drug Designation for the treatment … ongoing clinical trials and anticipated clinical trials for …

… a promising investigational medicine when preliminary clinical … -12 AXS-12 (reboxetine) is a highly … Drug Administration (FDA) Breakthrough Therapy designation and Orphan Drug Designation for the treatment … clinical trials and anticipated clinical trials for …

… year. While the NASDAQ Biotechnology Index has risen ~11. … FDA approval for Pitolisant for EDS in narcolepsy, Avadel Pharmaceuticals … Phase 3 trials in 2H 2020. Also known as reboxetine, AXS … drug is undergoing a pivotal Phase 2/3 trial for the treatment …

… trials of patients treated with reboxetine, and to other reboxetine intellectual property. Reboxetine … for the treatment of depression. Reboxetine is the active pharmaceutical ingredient in … treatments currently approved by the FDA. In a Phase 3 trial …

… Pharmaceuticals, a biotechnology company specializing in the development of novel treatments … drug availability through the end of Phase II clinical trials … for reboxetine, the active pharmaceutical ingredient in … trial of esreboxetine in the treatment of …